JP2023507033A5 - - Google Patents
Info
- Publication number
- JP2023507033A5 JP2023507033A5 JP2022538373A JP2022538373A JP2023507033A5 JP 2023507033 A5 JP2023507033 A5 JP 2023507033A5 JP 2022538373 A JP2022538373 A JP 2022538373A JP 2022538373 A JP2022538373 A JP 2022538373A JP 2023507033 A5 JP2023507033 A5 JP 2023507033A5
- Authority
- JP
- Japan
- Prior art keywords
- mutations
- domain
- polypeptide
- protein complex
- numbering
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962951701P | 2019-12-20 | 2019-12-20 | |
| US62/951,701 | 2019-12-20 | ||
| PCT/CA2020/051753 WO2021119832A1 (en) | 2019-12-20 | 2020-12-18 | Polypeptides, protein complexes and method for making same |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023507033A JP2023507033A (ja) | 2023-02-20 |
| JP2023507033A5 true JP2023507033A5 (enExample) | 2023-12-27 |
Family
ID=76476896
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022538373A Pending JP2023507033A (ja) | 2019-12-20 | 2020-12-18 | ポリペプチド、タンパク質複合体及びそれを作製する方法 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20230242676A1 (enExample) |
| EP (1) | EP4077374A4 (enExample) |
| JP (1) | JP2023507033A (enExample) |
| CN (1) | CN115003693A (enExample) |
| AR (1) | AR120870A1 (enExample) |
| CA (1) | CA3171363A1 (enExample) |
| TW (1) | TWI907375B (enExample) |
| WO (1) | WO2021119832A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3231417A1 (en) * | 2021-09-10 | 2023-03-16 | Jian Shi | Anti-ang2 antibody, preparation method therefor, and application thereof |
| EP4408893A4 (en) | 2021-09-29 | 2026-02-18 | Kisoji Biotechnology Inc | Binding agents targeting tumor cells expressing too much 2 |
| TWI876227B (zh) * | 2021-11-17 | 2025-03-11 | 大陸商南京再明醫藥有限公司 | 多特異性抗體及其藥物用途 |
| EP4599066A1 (en) * | 2022-10-03 | 2025-08-13 | Kisoji Biotechnology Inc. | Multispecific binding agents targeting dopamine receptor d2 and methods of use thereof |
| EP4608867A1 (en) * | 2022-10-25 | 2025-09-03 | Kisoji Biotechnology Inc. | Binding agents targeting cd36-expressing tumor cells |
| PE20252392A1 (es) | 2022-12-12 | 2025-10-10 | Lanova Medicines Ltd | Anticuerpos biespecificos que se dirigen a pd1 y vegf |
| CN121419995A (zh) * | 2023-04-04 | 2026-01-27 | 加拿大商木曾路生物科技公司 | 靶向表达trop2的肿瘤细胞的结合剂 |
| EP4520768A1 (en) | 2023-09-06 | 2025-03-12 | BioNTech SE | Vhh-ch3 fusion proteins |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013012733A1 (en) * | 2011-07-15 | 2013-01-24 | Biogen Idec Ma Inc. | Heterodimeric fc regions, binding molecules comprising same, and methods relating thereto |
| RS60499B1 (sr) * | 2011-12-20 | 2020-08-31 | Medimmune Llc | Modifikovani polipeptidi za bispecifične skelete antitela |
| US20160257748A1 (en) * | 2013-09-25 | 2016-09-08 | Amgen Inc. | V-c-fc-v-c antibody |
| MX380658B (es) * | 2014-01-15 | 2025-03-11 | Hoffmann La Roche | Variantes de region fc con union mejorada de la proteina a. |
| EP4299595A3 (en) * | 2014-05-02 | 2024-03-13 | Momenta Pharmaceuticals, Inc. | Compositions and methods related to engineered fc constructs |
| ES2846881T3 (es) * | 2015-05-01 | 2021-07-30 | Inhibrx Inc | Moléculas que se dirigen al sistema de secreción de tipo III |
| WO2016192613A1 (zh) * | 2015-06-01 | 2016-12-08 | 中山大学 | 具有融合至常规Fab片段的单域抗原结合片段的二价抗体 |
| KR20180098671A (ko) * | 2016-01-11 | 2018-09-04 | 인히브릭스, 인크. | 다가 및 다중특이적 ox40-결합 융합 단백질 |
| KR20180096789A (ko) * | 2016-01-11 | 2018-08-29 | 인히브릭스, 인크. | 다가 및 다중특이적 41bb-결합 융합 단백질 |
| CN110177805B (zh) * | 2016-10-19 | 2024-04-02 | 英温拉公司 | 抗体构建体 |
| JP7543134B2 (ja) * | 2017-10-03 | 2024-09-02 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング | システイン操作された抗原結合分子 |
| KR20200118423A (ko) * | 2018-01-08 | 2020-10-15 | 난징 레전드 바이오테크 씨오., 엘티디. | 다중특이성 항원 결합 단백질 및 이의 사용 방법 |
| SG11202008474QA (en) * | 2018-03-27 | 2020-10-29 | Systimmune Inc | Guidance and navigation control proteins and method of making and using thereof |
-
2020
- 2020-12-18 EP EP20902077.5A patent/EP4077374A4/en active Pending
- 2020-12-18 JP JP2022538373A patent/JP2023507033A/ja active Pending
- 2020-12-18 WO PCT/CA2020/051753 patent/WO2021119832A1/en not_active Ceased
- 2020-12-18 CA CA3171363A patent/CA3171363A1/en active Pending
- 2020-12-18 CN CN202080094676.5A patent/CN115003693A/zh active Pending
- 2020-12-18 US US17/786,708 patent/US20230242676A1/en active Pending
- 2020-12-21 TW TW109145364A patent/TWI907375B/zh active
- 2020-12-21 AR ARP200103608A patent/AR120870A1/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023507033A5 (enExample) | ||
| JP2025000628A5 (enExample) | ||
| JP2021525546A5 (enExample) | ||
| JP2021508469A5 (enExample) | ||
| JP2019525738A5 (enExample) | ||
| JP2021524268A5 (enExample) | ||
| JP2021098732A5 (enExample) | ||
| JP2021510521A5 (enExample) | ||
| RU2021110369A (ru) | Белки, связывающие nkg2d, cd16 и опухолеассоциированный антиген | |
| JP2023518134A5 (enExample) | ||
| JP2023509448A5 (enExample) | ||
| US12098203B2 (en) | Hetero-dimeric multi-specific antibody format targeting at least CD3 and HSA | |
| JP2021534762A5 (enExample) | ||
| JP2021524267A5 (enExample) | ||
| JP2023538945A5 (enExample) | ||
| JP2021503455A5 (enExample) | ||
| JP2023516004A5 (enExample) | ||
| JP2022504802A5 (enExample) | ||
| JP2018502050A5 (enExample) | ||
| JP2018537966A5 (enExample) | ||
| JP2021520832A5 (enExample) | ||
| JP2014158485A5 (enExample) | ||
| JP2022545647A5 (enExample) | ||
| JP2021515798A5 (enExample) | ||
| IL276903B1 (en) | Bispecific egfr/cd16 antigen-binding protein |